PharmaEssentia (6446 TW) stock market data APIs
NT$952.6962
0.79(0.1%)
as of June 12, 2026
Try our APIs with
free plan!
PharmaEssentia Financial Data Overview
Price chart is built with
Anychart
PharmaEssentia Corporation, a biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan. Its products include BESREMi, an interferon therapy indicated for polycythemia vera, essential thrombocythemia, PMF, and adult T-cell leukemias. The company also develops Ropeg + anti PD-1; PEG-IL-2 (P11838); PEG-Cytokines; PD-1-IL-2v; ADC; ADCS; NY-ESO-1 TCR-T; and Novel TCR-T for the treatment of solid tumor and immunology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.
Prev. Close
952.6962
Open
953.4886
High
970.0827
Low
921.0123
52 wk Range
440.6474-1020
Market Cap
352 677 M
P/E Ratio
69.5748
Shares Outstanding
372 M
Revenue
17 499 M
EPS
5.78
Dividends (Yield)
0.0012
Beta
0.607
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with PharmaEssentia (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get PharmaEssentia data using free add-ons & libraries
Get PharmaEssentia Fundamental Data
PharmaEssentia Fundamental data includes:
- Net Revenue: 17 499 M
- EBITDA: 6 063 M
- Earnings Per Share: 13
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-14
- EPS/Forecast: 4.25
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
PharmaEssentia News
New
PharmaEssentia Expands North American Commercial Footprint with Acquisition of Canadian Partner FORUS Therapeutics
Acquisition deepens PharmaEssentia's presence in the Canadian hematology-oncology MPN market to accelerate BESREMi® (ropeginterferon alfa-2b) commercialization BURLINGTON, Mass., June 11, 2026--(BUS...
PharmaEssentia Announces Taiwan Approval of BESREMi® for Essential Thrombocythemia, Marking First Global Approval in ET
First global approval of BESREMi® in essential thrombocythemia supports continued expansion of the PharmaEssentia MPN franchise; U.S. PDUFA date remains on track for August 30, 2026 BESREMi® become...
High Growth Tech Stocks To Watch In Asia June 2026
Amid a backdrop of mixed economic signals and market volatility, Asian tech stocks have drawn significant attention as investors navigate the shifting landscape. With key indices reflecting varied per...
High Growth Tech Stocks In Asia Featuring Damai Entertainment Holdings And 2 Others
In recent weeks, Asian markets have been navigating a complex landscape influenced by global geopolitical developments and economic indicators. As investor sentiment remains buoyant with optimism surr...
Get PharmaEssentia fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
